united healthcare glp 1 coverage Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss GLP-1s and The Payer Predicament
Description
Find out.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes

manufactured in cGMP-certified facilities, third-party tested for purity, and non-GMO, gluten-free, with zero artificial additives or fillers
Eli Lilly has just launched its newly approved GLP-1 product, Zepbound, in a direct-to-consumer approach

Conclusions LSG produces sustained weight loss and metabolic benefits in adolescents